SAFE AND EFFECTIVE TOPICAL MEDICATION (SOLUTION, CREAM & PATCH) TO TREAT CUTANEOUS HEMANGIOMA

Suqin Guo (Inventor)

Research output: Innovation

Abstract


Invention Summary:

C apillary hemangioma is the most common benign tumor of the eyelid/orbit in children and affects up to 2% of infants, over 1.7 million children in USA and over 10 million children worldwide. If not treated promptly, it can cause blindness. Overall, the incidence of cutaneous hemangioma is widely prevalent resulting in physically disfiguring and psychologically disturbing lesions in all age groups affected. Systemic or intra-lesional corticosteroids are commonly used as first line treatment. Alternative treatments include laser photocoagulation, surgical excision and immunomodulators. However, most of the treatment options are associated with complications such as myelosuppression and hepatotoxicity for cyclophosphamide, and neurotoxicity (spastic displagia) for interferon alfa-2a, increased risk of hypertension, adrenal cortical insufficiency, growth delay, immunosupression, gastrointestinal bleeding, diabetes mellitus, weight gain, and behavioral changes. Intra-lesional corticosteroid injection can cause local complications including dystrophic periocular calcifications, skin hypopigmentation, eyelid necrosis (disfiguring) central retinal artery occlusion (sudden blindness) and adrenal suppression (growth retardation in children). Most recently, a systemic application of propranolol was reported to successfully treat severe hemangioma of infants. However, oral application of propranolol can cause severe systemic complications such as bronchospasm, vasospasm, systemic lupus erythematosus, heart block, severe bradycardia, and congestive heart failure.

Researchers at Rutgers have discovered a novel therapeutic approach to avoid the above mentioned systemic or life threatening complications of the beta-blocker medication. The invention involves the use of a topical nonselective beta-blocker with strong beta2 antagonist activity in the form of a solution, cream, ointment or patch with concentration between 0.1% to 50% applied directly to treat cutaneous hemangioma in the human body, starting with the treatment of capillary hemangioma of the eyelids in children.

Market Applications:

Treat Cutaneous and Capillary Hemangioma

Advantages:

  • Treat Cutaneous and Capillary Hemangioma
  • More effective treatment
  • Safe & Simple application
  • Easy monitoring
  • Little to no systemic complications with reduced doctor’s visits

Intellectual Property & Development Status:

Published United States application: US-2012-0058056-A1

Original languageEnglish (US)
StatePublished - Feb 2014

Fingerprint

Hemangioma
Capillary Hemangioma
Skin
Eyelids
Blindness
Propranolol
Adrenal Cortex Hormones
Therapeutics
Retinal Artery Occlusion
Intellectual Property
Hypopigmentation
Adrenal Insufficiency
Bronchial Spasm
Heart Block
Muscle Spasticity
Light Coagulation
Immunologic Factors
Orbit
Bradycardia
Growth

Keywords

  • Ophthalmology
  • Small Molecules

Cite this

@misc{950d1ac6edc74f289bc0e83555e93908,
title = "SAFE AND EFFECTIVE TOPICAL MEDICATION (SOLUTION, CREAM & PATCH) TO TREAT CUTANEOUS HEMANGIOMA",
abstract = "Invention Summary: C apillary hemangioma is the most common benign tumor of the eyelid/orbit in children and affects up to 2{\%} of infants, over 1.7 million children in USA and over 10 million children worldwide. If not treated promptly, it can cause blindness. Overall, the incidence of cutaneous hemangioma is widely prevalent resulting in physically disfiguring and psychologically disturbing lesions in all age groups affected. Systemic or intra-lesional corticosteroids are commonly used as first line treatment. Alternative treatments include laser photocoagulation, surgical excision and immunomodulators. However, most of the treatment options are associated with complications such as myelosuppression and hepatotoxicity for cyclophosphamide, and neurotoxicity (spastic displagia) for interferon alfa-2a, increased risk of hypertension, adrenal cortical insufficiency, growth delay, immunosupression, gastrointestinal bleeding, diabetes mellitus, weight gain, and behavioral changes. Intra-lesional corticosteroid injection can cause local complications including dystrophic periocular calcifications, skin hypopigmentation, eyelid necrosis (disfiguring) central retinal artery occlusion (sudden blindness) and adrenal suppression (growth retardation in children). Most recently, a systemic application of propranolol was reported to successfully treat severe hemangioma of infants. However, oral application of propranolol can cause severe systemic complications such as bronchospasm, vasospasm, systemic lupus erythematosus, heart block, severe bradycardia, and congestive heart failure. Researchers at Rutgers have discovered a novel therapeutic approach to avoid the above mentioned systemic or life threatening complications of the beta-blocker medication. The invention involves the use of a topical nonselective beta-blocker with strong beta2 antagonist activity in the form of a solution, cream, ointment or patch with concentration between 0.1{\%} to 50{\%} applied directly to treat cutaneous hemangioma in the human body, starting with the treatment of capillary hemangioma of the eyelids in children. Market Applications: Treat Cutaneous and Capillary Hemangioma Advantages: Treat Cutaneous and Capillary Hemangioma More effective treatment Safe & Simple application Easy monitoring Little to no systemic complications with reduced doctor’s visits Intellectual Property & Development Status: Published United States application: US-2012-0058056-A1",
keywords = "Ophthalmology, Small Molecules",
author = "Suqin Guo",
year = "2014",
month = "2",
language = "English (US)",
type = "Patent",

}

TY - PAT

T1 - SAFE AND EFFECTIVE TOPICAL MEDICATION (SOLUTION, CREAM & PATCH) TO TREAT CUTANEOUS HEMANGIOMA

AU - Guo, Suqin

PY - 2014/2

Y1 - 2014/2

N2 - Invention Summary: C apillary hemangioma is the most common benign tumor of the eyelid/orbit in children and affects up to 2% of infants, over 1.7 million children in USA and over 10 million children worldwide. If not treated promptly, it can cause blindness. Overall, the incidence of cutaneous hemangioma is widely prevalent resulting in physically disfiguring and psychologically disturbing lesions in all age groups affected. Systemic or intra-lesional corticosteroids are commonly used as first line treatment. Alternative treatments include laser photocoagulation, surgical excision and immunomodulators. However, most of the treatment options are associated with complications such as myelosuppression and hepatotoxicity for cyclophosphamide, and neurotoxicity (spastic displagia) for interferon alfa-2a, increased risk of hypertension, adrenal cortical insufficiency, growth delay, immunosupression, gastrointestinal bleeding, diabetes mellitus, weight gain, and behavioral changes. Intra-lesional corticosteroid injection can cause local complications including dystrophic periocular calcifications, skin hypopigmentation, eyelid necrosis (disfiguring) central retinal artery occlusion (sudden blindness) and adrenal suppression (growth retardation in children). Most recently, a systemic application of propranolol was reported to successfully treat severe hemangioma of infants. However, oral application of propranolol can cause severe systemic complications such as bronchospasm, vasospasm, systemic lupus erythematosus, heart block, severe bradycardia, and congestive heart failure. Researchers at Rutgers have discovered a novel therapeutic approach to avoid the above mentioned systemic or life threatening complications of the beta-blocker medication. The invention involves the use of a topical nonselective beta-blocker with strong beta2 antagonist activity in the form of a solution, cream, ointment or patch with concentration between 0.1% to 50% applied directly to treat cutaneous hemangioma in the human body, starting with the treatment of capillary hemangioma of the eyelids in children. Market Applications: Treat Cutaneous and Capillary Hemangioma Advantages: Treat Cutaneous and Capillary Hemangioma More effective treatment Safe & Simple application Easy monitoring Little to no systemic complications with reduced doctor’s visits Intellectual Property & Development Status: Published United States application: US-2012-0058056-A1

AB - Invention Summary: C apillary hemangioma is the most common benign tumor of the eyelid/orbit in children and affects up to 2% of infants, over 1.7 million children in USA and over 10 million children worldwide. If not treated promptly, it can cause blindness. Overall, the incidence of cutaneous hemangioma is widely prevalent resulting in physically disfiguring and psychologically disturbing lesions in all age groups affected. Systemic or intra-lesional corticosteroids are commonly used as first line treatment. Alternative treatments include laser photocoagulation, surgical excision and immunomodulators. However, most of the treatment options are associated with complications such as myelosuppression and hepatotoxicity for cyclophosphamide, and neurotoxicity (spastic displagia) for interferon alfa-2a, increased risk of hypertension, adrenal cortical insufficiency, growth delay, immunosupression, gastrointestinal bleeding, diabetes mellitus, weight gain, and behavioral changes. Intra-lesional corticosteroid injection can cause local complications including dystrophic periocular calcifications, skin hypopigmentation, eyelid necrosis (disfiguring) central retinal artery occlusion (sudden blindness) and adrenal suppression (growth retardation in children). Most recently, a systemic application of propranolol was reported to successfully treat severe hemangioma of infants. However, oral application of propranolol can cause severe systemic complications such as bronchospasm, vasospasm, systemic lupus erythematosus, heart block, severe bradycardia, and congestive heart failure. Researchers at Rutgers have discovered a novel therapeutic approach to avoid the above mentioned systemic or life threatening complications of the beta-blocker medication. The invention involves the use of a topical nonselective beta-blocker with strong beta2 antagonist activity in the form of a solution, cream, ointment or patch with concentration between 0.1% to 50% applied directly to treat cutaneous hemangioma in the human body, starting with the treatment of capillary hemangioma of the eyelids in children. Market Applications: Treat Cutaneous and Capillary Hemangioma Advantages: Treat Cutaneous and Capillary Hemangioma More effective treatment Safe & Simple application Easy monitoring Little to no systemic complications with reduced doctor’s visits Intellectual Property & Development Status: Published United States application: US-2012-0058056-A1

KW - Ophthalmology

KW - Small Molecules

UR - http://rutgers.technologypublisher.com/tech?title=SAFE_AND_EFFECTIVE_TOPICAL_MEDICATION_(SOLUTION%2c_CREAM_%2b_PATCH)_TO_TREAT_CUTANEOUS_HEMANGIOMA

M3 - Innovation

ER -